Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
The data was accessed by a Western-based hacking group known as ShinyHunters. The information is said to include viewing habits, search history and location data. Data belonging to more than 200 ...
Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular drug aficamten. Reports that ...
AI systems could produce 80 million tons of CO₂ in 2025 and as much water as the world’s bottled water industry. But it’s hard to measure as tech companies do not release all of the details.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback